Business
Investor Presentation in Manchester
Investor Presentation in Manchester.
About this update from Valirx Plc
[{"type":"text","content":"\n \nRNS Number : 7174H ValiRx PLC 25 June 2013 \n\n \n \n \n \n \nFor release at 07:00 on 25 June 2013\n \n \nValiRx Plc\n(\"ValiRx\" or the \"Company\")\nINVESTOR PRESENTATION\n\"Presentation at Proactive Investors One2One Investor Forum\n in Manchester\"\n \n \nValiRx Plc (AIM: VAL), a life science company with a focus on cancer therapeutics for personalised medicine, is pleased to announce that Dr Satu Vainikka, Chief Executive of ValiRx plc will be making a presentation at the Proactive Investors One2One Investor Forum, The Midland Hotel, Peter Street, Manchester on Wednesday, 26 June 2013. \n \nFurther information can be obtained at www.proactiveinvestors.co.uk\n \nThe slides will be available from the Company's website, www.valirx.comafter the event.\n \n- ENDS -\nFor more information, please contact:\n\n\n\n\nValiRx plc\n\n\nTel: +44 (0) 20 3008 4416\n\n\n\n\nDr Satu Vainikka\n\n\nwww.ValiRx.com\n\n\n\n\n\n\n\n\n\n\n\n\nCairn Financial Advisers LLP (Nominated Adviser)\n\n\nTel:+44 (0) 20 7148 7900\n\n\n\n\nLiam Murray / Avi Robinson\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nHybridan LLP (Broker)\n\n\nTel: +44 (0) 20 7947 4350 / 4361\n\n\n\n\nClaire Louise Noyce / William Lynne\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPeckwater PR\n\n\nTel: +44 (0)7879 458 364\n\n\n\n\nTarquin Edwards\n\n\[email protected]\n\n\n\n\n\n\n\n\n\n\n\n\n \nAbout ValiRx Plc\nValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.\n \nThe Company listed on AIM in October 2006 and is creating a portfolio of innovative products through investment in specific development projects. It actively manages projects within this portfolio as a trading company and is not an investment vehicle. The ValiRx business model spreads the risks of life science technology developments by minimising financial exposure and running a set of projects to defined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are the greatest.\n \nThe Company op...